Update on poly(ADP-ribose) polymerase inhibitors resistance in ovarian cancer

Ovarian cancer is one of the most common reproductive system tumors. The incidence of ovarian cancer in China is on the rise. Poly(ADP-ribose) polymerase (PARP) inhibitor (PARPi) is a DNA repair enzyme associated with DNA damage repair. PARPi takes PARP as a target to kill tumor cells, especially for tumors with homologous recombination (HR) dysfunction. Currently, PARPi has been widely used in clinical practice, mainly for the maintenance of advanced ovarian epithelial cancer. The intrinsic or acquired drug resistance of PARPi has gradually become an important clinical problem with the wide application of PARPi. This review summarizes the mechanisms of PARPi resistance and the current progress on PARPi-based combination strategies.

Automated summary

Ovarian cancer is a common reproductive system tumor with increasing incidence in China. Poly(ADP-ribose) polymerase inhibitor (PARPi) targets DNA repair enzyme PARP to kill tumor cells, particularly those with HR dysfunction. PARPi has been widely used in clinical practice for maintenance therapy of advanced ovarian epithelial cancer. However, the development of intrinsic or acquired drug resistance to PARPi has become a significant clinical problem. This review summarizes the mechanisms of PARPi resistance and current progress on PARPi-based combination strategies.